{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:03:05Z","timestamp":1787785385601,"version":"build-2784847793"},"reference-count":37,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NPO Western Japan Society for Inflammatory Skin Diseases"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease with substantial impact on quality of life. The introduction of biologics and Janus kinase (JAK) inhibitors has markedly transformed systemic treatment strategies. However, long-term prospective real-world registries evaluating drug survival, safety, phenotype-specific treatment response, and post-discontinuation outcomes remain limited, particularly in Asian populations. Methods: The Western Japan Atopic Dermatitis Registry (WJADR) is a multicenter, prospective, observational registry coordinated by Kyushu University and collaborating institutions across western Japan. Patients initiating or currently receiving systemic therapy for AD are enrolled. Longitudinal data collection includes clinical phenotype classification, disease course classification, treatment exposure, physician-assessed severity scores, patient-reported outcomes, biomarkers, and safety information. The primary outcome is drug survival, while secondary outcomes include clinical improvement, adverse events, phenotype\u2013treatment interactions, biomarker\u2013treatment correlations, and treatment-switch patterns. Results: WJADR was designed as a phenotype-integrated real-world registry to evaluate comprehensive systemic treatment strategies and post-discontinuation outcomes in AD prior to the completion of patient enrollment and outcome analyses. Unlike existing registries primarily focused on biologic initiator cohorts or treatment burden, WJADR integrates clinical phenotypes, biomarkers, and longitudinal outcomes to support precision medicine approaches. Conclusions: WJADR represents the first large-scale multicenter prospective AD registry in western Japan and may provide ethnicity-specific real-world evidence to support long-term safety evaluation, treatment optimization, and phenotype-guided therapeutic strategies in AD.<\/jats:p>","DOI":"10.3390\/jcm15135232","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:01:37Z","timestamp":1783339297000},"page":"5232","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Western Japan Atopic Dermatitis Registry (WJADR): A Multicenter Real-World Registry of Systemic Therapies for Atopic Dermatitis"],"prefix":"10.3390","volume":"15","author":[{"given":"Kazuhiko","family":"Yamamura","sequence":"first","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Yotsumoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9394-653X","authenticated-orcid":false,"given":"Emi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka 814-0180, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakae","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Masuda Red Cross Hospital, Masuda 698-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Oita University, Oita 879-5593, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka 814-0180, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-8273","authenticated-orcid":false,"given":"Takeshi","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaip.2014.03.006","article-title":"Skin barrier and immune dysregulation in atopic dermatitis: An evolving story with important clinical implications","volume":"2","author":"Czarnowicki","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamadermatol.2020.0796","article-title":"Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis","volume":"156","author":"Drucker","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1111\/1346-8138.17544","article-title":"English version of clinical practice guidelines for the management of atopic dermatitis 2024","volume":"52","author":"Saeki","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): Results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Teixeira","year":"2021","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: Results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2324833","DOI":"10.1080\/09546634.2024.2324833","article-title":"Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials","volume":"35","author":"Hebert","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): Results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: An expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Yamamura, K., and Nakahara, T. (2022). The Dawn of a New Era in Atopic Dermatitis Treatment. J. Clin. Med., 11.","DOI":"10.3390\/jcm11206145"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jaip.2025.10.052","article-title":"Systemic Therapy for Atopic Dermatitis: Choosing Biologics or Janus Kinase Inhibitors for Children and Adults","volume":"14","author":"Scholl","year":"2026","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaci.2024.04.009","article-title":"Biologic and small-molecule therapy for treating moderate to severe atopic dermatitis: Mechanistic considerations","volume":"154","author":"Bar","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.jid.2017.05.014","article-title":"The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries","volume":"137","author":"Spuls","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/bjd.16714","article-title":"TREatment of ATopic eczema (TREAT) Registry Taskforce: An international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries","volume":"180","author":"Gerbens","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/bjd.18452","article-title":"TREatment of ATopic eczema (TREAT) Registry Taskforce: Protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema","volume":"182","author":"Bosma","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/jdv.18566","article-title":"Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce","volume":"37","author":"Bosma","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jdv.20876","article-title":"Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce","volume":"39","author":"Musters","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/1346-8138.14787","article-title":"Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden","volume":"46","author":"Katoh","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s13555-025-01395-1","article-title":"Complete\/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry","volume":"15","author":"Bhatia","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","article-title":"Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry","volume":"84","author":"Spekhorst","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s12325-024-03049-8","article-title":"One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis","volume":"42","author":"Chu","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1080\/09546634.2022.2043545","article-title":"Dupilumab for the treatment of atopic dermatitis: Real-world data from the Czech Republic BIOREP registry","volume":"33","author":"Kojanova","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.alit.2021.07.003","article-title":"Subtypes of atopic dermatitis: From phenotype to endotype","volume":"71","author":"Tokura","year":"2022","journal-title":"Allergol. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-025-59340-x","article-title":"An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis","volume":"16","author":"Kawasaki","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/1346-8138.16092","article-title":"Establishment of the Western Japan Psoriasis Registry and first cross-sectional analysis of registered patients","volume":"48","author":"Tsuruta","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/1346-8138.17385","article-title":"Real-world safety and efficacy of biologics in elderly patients with psoriasis: A multicenter observational study","volume":"51","author":"Ohata","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/1346-8138.17245","article-title":"Systemic therapy for psoriasis and the risk of cutaneous infections","volume":"51","author":"Higashi","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/25785826.2025.2567133","article-title":"A new era in atopic dermatitis treatment and evolving therapeutic strategies","volume":"49","author":"Honda","year":"2026","journal-title":"Immunol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"adv00731","DOI":"10.2340\/actadv.v102.295","article-title":"Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab","volume":"102","author":"Miyamoto","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.anai.2020.07.026","article-title":"Real-world persistence with dupilumab among adults with atopic dermatitis","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5232\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:06:28Z","timestamp":1783685188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":37,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135232"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135232","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]}}}